Alefacept dosing

Alefacept (Amevive) is a dimeric fusion protein that binds to CD2 on T cells to inhibit cutaneous T-cell activation and proliferation. It also produces a dose-dependent decrease in circulating total lymphocytes. Alefacept is approved for treatment of moderate to severe plaque psoriasis and is also effective for treatment of psoriatic arthritis. Significant response is usually achieved after about 3 months of therapy. The recommended dose is 15 mg intramuscularly once weekly for 12 weeks. Adverse effects are mild and include pharyngitis, flu-like symptoms, chills, dizziness, nausea, headache, injection site pain and inflammation, and nonspecific infection. 

Alefacept is a dimeric fusion protein that combines the first extracellular domain of human LFA-3 with the Ec portion of human IgGi. The LFA-3 segment of alefacept binds specifically to CD2 on T cells to prevent costimulatory signals delivered by LEA-3 and thereby inhibit cutaneous T-ceU activation and proliferation. Alefacept also induces selective apoptosis of memory-effector T cells and produces a dose-dependent decrease in circulating total lymphocytes. ... 

Alefacept is administered by intramuscular injection in once-weekly doses of 15 mg for 12 weeks. 

---